Увійти

Готові списки джерел за темами / Pregnancy disease / Статті в журналах

Статті в журналах з теми "Pregnancy disease"

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Pregnancy disease.

Автор: Grafiati

Опубліковано: 14 березня 2024

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Pregnancy disease".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Batyrovna, Tilyakhodjaeva Gulbakhor. "PECULIARITIES OF VARICOSE VEIN DISEASE IN PREGNANCY." International Journal of Medical Sciences And Clinical Research 02, no. 04 (April 1, 2022): 1–6. http://dx.doi.org/10.37547/ijmscr/volume02issue04-01.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The article under discussion depicts peculiarities of varicose vein disease in pregnancy. Venous disease in women often complicates pregnancy, childbirth and the postpartum period. Venous insufficiency complicates pregnancy, delivery and postpartum period and leads to increased maternal morbidity and mortality. The author of the article considers that correction of placental dysfunction, especially in the early stages, can significantly improve perinatal outcomes.

2

Dissemond, Joachim, Philipp Al Ghazal, Katharina Herberger, Jörg Schaller, and Anke Strölin. "Significant Exacerbation of Darier's Disease and Pregnancy." Dermatology and Dermatitis 3, no. 1 (October 1, 2018): 01–04. http://dx.doi.org/10.31579/2578-8949/044.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Darier's disease, also known as keratosis follicularis or Darier-White disease, is an autosomal dominant inherited condition. The disease usually has its onset in the teenage years, meaning it co-exists with the years of fertility in women. The potential dermatological and obstetric implications of Darrier's Disease, especially when it involves the groin and vulva, have not been well reported. We report a case of Darier's Disease associated with multiple antibiotic resistant folliculitis involving skin of the breasts, groin, vulva and perineum that precluded safe vaginal delivery.

3

Modiya, Dr Rohan A., Dr Shirish B. Raval, and Dr Seema S. Khetani. "Outcome in Rheumatic Heart Disease in Pregnancy." International Journal of Scientific Research 1, no. 7 (June 1, 2012): 159–60. http://dx.doi.org/10.15373/22778179/dec2012/58.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Rakhimovna, Khudoyarova Dildora, and Yusupov Orzimurod Shomurodovich. "VARICOSE DISEASE AND PRECNANCY." International Journal of Medical Sciences And Clinical Research 03, no. 04 (April 1, 2023): 50–54. http://dx.doi.org/10.37547/ijmscr/volume03issue04-07.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The article presents observational data of patients with varicose veins and analyzes the course of pregnancy. The patients were divided into three groups depending on the type of varicose veins, the control group consisted of healthy pregnant women who developed varicose veins during this pregnancy. The work was carried out on the basis of the Department of Obstetrics and Gynecology No. 1 of the Samarkand State Medical University. The study revealed exacerbation of the phenomena of varicose veins in the second - third trimester of pregnancy, as well as complications of pregnancy compared with the control group.

5

Golovach, I. Yu, and Ye D. Yehudina. "Perygravid management of rheumatic disease." HEALTH OF WOMAN, no. 2(148) (March 30, 2020): 42–51. http://dx.doi.org/10.15574/hw.2020.148.42.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Management of inflammatory rheumatic diseases in preconception period, pregnancy and breastfeeding has undergone significant changes over the past few years. Modern therapy, including biological and targeted synthetic disease modifying drugs, has significantly improved the control of rheumatic diseases, which has led to an increase in the patients’ number planning a pregnancy with serious diseases. When consulting such patients, it is necessary to discuss the possible time of conception (regarding the activity of the disease), the effect of the disease on pregnancy and pregnancy on the disease, as well as the potential need to change the regimen of medications during pregnancy and breastfeeding. This review summarizes information on the effects of pregnancy on various rheumatic diseases and vice versa, changes in therapy and monitoring of patients with rheumatic diseases before, during and after pregnancy. Women with inflammatory rheumatic diseases need advice on drug therapy before planning pregnancy, during pregnancy, and breastfeeding. Safe disease-modifying drugs that can be taken during pregnancy are hydroxychloroquine, sulfosalazine, azathioprine, and cyclosporine. Glucocorticoids and non-steroidal anti-inflammatory drugs can also be taken up to 32 weeks of gestation. Most inhibitors of tumor necrosis factor (anti-TNF) are also safe during pregnancy. During pregnancy, a clear monitoring of the activity of the disease is necessary, control of the level of autoantibodies, especially anti-SSA / Ro and anti-SSB / La and antiphospholipid antibodies, an assessment of the degree of organ dysfunction, especially kidney damage. Presented are modern approaches to optimizing the management of inflammatory rheumatic disease during pregnancy. For patients with inflammatory rheumatic diseases, a successful pregnancy outcome is optimized by creating an individual plan to suppress disease activity using a targeted approach. Key words: pregnancy, rheumatic diseases, treatment, lactation, management tactics, drugs.

6

Davies, Gregory A. L., and William N. P. Herbert. "HEART DISEASE IN PREGNANCY 2: Congenital Heart Disease in Pregnancy." Journal of Obstetrics and Gynaecology Canada 29, no. 5 (May 2007): 409–14. http://dx.doi.org/10.1016/s1701-2163(16)35492-5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Vyas, Rupa, Priya Gupta, Sapana Shah, and Komal Rangoliya. "Cardiovascular disease in pregnancy." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 8, no. 9 (August 26, 2019): 3789. http://dx.doi.org/10.18203/2320-1770.ijrcog20193821.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Background: Maternal cardiac disease is a major cause of non-obstetric maternal morbidity and mortality. The care of pregnant women with cardiac disease requires a multidisciplinary approach, involving obstetricians, cardiologists and anesthesiologist.Methods: A prospective analytical study of maternal heart disease and its fetomaternal outcome is carried out in the department of obstetrics and gynecology at tertiary hospital and teaching institute. The study was carried out on 50 cases belonging to age group 18-50 years with various cardiac diseases during their pregnancy and peripartum period.Results: In this study, 78% of the cases were registered with our hospital. The present study shows about 32% of the women having cardiac disease were in the age group of 20-25 years. 34% belonged to NYHA class II and had a relatively uneventful peripartum period. Among all forms of heart disease, RHD was common constituting 26% of cases. Most common condition associated with cardiac disease in pregnancy was preeclampsia (36%) in our study, with anemia being other one (10%). The common complications were congestive cardiac failure (12%) and pulmonary edema (8%). Combination of diuretics and beta blockers was used most commonly (22%). 56% of women delivered with caesarean section. 42 patients delivered after age of viability with 29 (69%) term deliveries and 13 (30%) preterm deliveries with 8 requiring NICU care.Conclusions: Valvular heart disease of rheumatic origin is the most common cardiac disease associated with pregnancy.The availability of adequate systems of early diagnosis of cardiac lesion, reference to tertiary care center & close monitoring of patient and delivery with multidisciplinary approach include specialized cardiologic care, high risk obstetric support and neonatology expertise that can minimize the serious consequences and helps to improve fetomaternal outcome. Pre-conceptional counseling and surgical correction of certain conditions improves maternal as well as fetal outcome. Awareness needs to be created about heart diseases during pregnancy and the importance of regular antenatal check-ups.

8

Erez, Y., S. B. Kocaer, G. Can, M. Birlik, F. Onen, and İ. Sari. "AB0769 Treatment outcomes of patients with biological therapy during pregnancy and effect of pregnancy planning on treatment preferance of rheumatologists." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1511.1–1511. http://dx.doi.org/10.1136/annrheumdis-2022-eular.3115.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

BackgroundRheumatic diseases occur mostly in adults at reproductive age. In addition to the impact of disease course on fetal and maternal health, safety concerns regarding the effects of biological drugs on the course of pregnancy have come to the fore with the introduction and widespread use of them. Unlike other biological treatments, all tumor necrosis factor (TNF) antagonists can be used during pregnancy.ObjectivesTo investigate clinical features, treatment characteristics and pregnancy outcomes of patients with biological treatment and evaluate impact of planning pregnancy on treatment preferance.MethodsThe study was planned between January 2015 and December 2021. Patients who received biological treatment at conception were determined retrospectively. Demographycal data, clinical features, treatment characteristics and pregnancy outcomes were recorded.Results15 patients (mean age 37.2±4) were included. Mean age at diagnosis was 25.6±5.4 and age at gestational was 33±3.9. Mean follow-up duration was 96±55 months. Median period of biological therapy was found 37 (1-156) months. Six (40%) patients were diagnosed with Axial Spondyloarthritis, 6 (40%) Psoriatic Arthritis, 1 (6.6%) Rheumatoid arthritis. While 12 (80%) patients had planned (wanted) pregnancies, 10 (66%) patients were evaluated as eligible for pregnancy in terms of rheumatological disease by rheumatologists. 13 (86.6%) patients were in remission/partial remission before pregnancy. 5 (33.3%) patients were using steroid and disease modifying anti-rheumatic drugs (DMARDs) were stopped before conception. 10 (66.6%) patients were receiving certolizumab, 4 (26.7%) patients were receiving adalimumab. It was found that the treatment of the patient who received rituximab was interrupted due to the pregnancy planning. While certolizumab treatment continued in 6 (60%) patients during pregnancy, the treatment of patients receiving adalimumab was discontinued within first trimester. Activation of disease was occurred in 2 patients whose therapy interrupted. Biological treatment was restarted during pregnancy in 3 of 9 patients whose biological treatment was discontinued. No perinatal complication was developed except premature rupture of membranes in one patient. It was observed that all infants were healthy at birth, but baby of the mother who received certolizumab was diagnosed mental retardation in early childhood.ConclusionIn this study, it was established that the majority of patients using TNF antagonist during pregnancy;1-Having wanted/planned pregnancy,2-Being in remission or low disease activity before pregnancy,3-Not experiencing disease activation during pregnancy.In this study, it was concluded that having a pregnancy plan may be an important factor for rheumatologists to decide type of TNF antagonist, and physicians tend to prefer certolizumab in patients with pregnancy plan.Table 1.Baseline clinical and treatment characteristicsAge, years37.2±4Age, at diagnosis25.6±5.4Age, at gestation33±3.9Follow-up duration, months96±55Biologic treatment duration, months37 (1-156)Rheumatologic diseasen (%) -Spondyloarthritis6 (40) -Psoriatic arthritis6 (40) -Rheumatoid arthritis1 (6.6) -Behcet disease1 (6.6) -Systemic lupus eritematosus1 (6.6)Biologic treatmentn (%) -Certolizumab*10 (66.6) -Adalimumab*4 (26.7)Discontinuation of treatment9 (60)Restart3 (33.3)Disease activityRemission/partial remission*13 (86.6)Activation during pregnancy3 (20)*At conceptionDisclosure of InterestsNone declared

9

N.I., Zakirova. "MANAGEMENT OF PREGNANT WOMEN WITH THYROID DISEASE." Frontline Medical Sciences and Pharmaceutical Journal 02, no. 03 (March 1, 2022): 122–27. http://dx.doi.org/10.37547/medical-fmspj-02-03-13.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The course of pregnancy, thyroid status, hormonal levels were studied in 96 women with autoimmune thyroiditis (AIT). It was found that pregnant women have a number of complications (54.8%) from the mother and the fetus, AIT has an unfavorable effect on the course of pregnancy, there is a high risk of miscarriage and termination of pregnancy, there is a decrease in the level of thyroid hormones and an increase in the level of TSH in comparison with similar indicators of healthy pregnant women. For the prevention of complications of gestation and prematurity of pregnancy in women with AIT, a planned determination of TSH blood from early gestation is recommended.

10

Gross man, R. F., and Sami Micheal. "Management Thyroid Disease in Pregnancy: Preconception, and the Postpartum Complications." Endocrinology and Disorders 1, no. 3 (December 5, 2017): 01–04. http://dx.doi.org/10.31579/2640-1045/012.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Pregnancy has a profound impact on the thyroid gland and thyroid function since the thyroid may encounter changes to hormones and size during pregnancy. The diagnosis and treatment of thyroid disease during pregnancy and the postpartum is complex but knowledge regarding the interaction between the thyroids and pregnancy/the postpartum period is advancing at a rapid pace. For women known to have hypothyroidism, an increase in thyroxine dose by 20–40% when pregnancy is confirmed usually ensures they remain euthyroid. Treatment of subclinical hypothyroidism is recommended if the woman has antithyroid antibodies. Treatment of hyperthyroidism, unless it is related to human chorionic gonadotrophin, involves propylthiouracil in the first trimester. Carbimazole may be used in the second trimester. Thyroid function tests are checked every month and every two weeks following a change in dose. Women with a current or a past history of Graves’ disease who have thyrotropin receptor antibodies require early specialist referral as there is a 1–5% risk of fetal hyperthyroidism. Women with thyroid disorders in pregnancy should be followed up by their GP in the postpartum period. Postpartum thyroiditis may present months after delivery.

11

Leslein, Nicholas. "Pregnancy and Lyme disease." Proceedings in Obstetrics and Gynecology 1, no. 1 (April 2, 2010): 1–4. http://dx.doi.org/10.17077/2154-4751.1011.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Elizabeth, N. Pearce, and M. Leung Angela. "Thyroid Disease in Pregnancy." US Endocrinology 04, no. 01 (2008): 100. http://dx.doi.org/10.17925/use.2008.04.01.100.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The spectrum of thyroid disease in pregnancy has implications for both the mother and the developing fetus. Here we review the interpretation of thyroid function test values, thyrotoxicosis, hypothyroidism, iodine requirements, autoimmune thyroid disease, and thyroid screening recommendations as they pertain to pregnant women. It should be noted that the management of thyroid dysfunction in pregnancy should be closely co-ordinated with obstetricians and other providers.

13

Hill, Alexandria J., and Luis D. Pacheco. "Cardiovascular Disease in Pregnancy." NeoReviews 13, no. 11 (November 2012): e651-e660. http://dx.doi.org/10.1542/neo.13-11-e651.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Atapattu, Piyusha. "Thyroid disease in pregnancy." Ceylon Medical Journal 52, no. 1 (September 9, 2009): 24. http://dx.doi.org/10.4038/cmj.v52i1.1044.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Blom, Kimberly, Ayodele Odutayo, Kate Bramham, and Michelle A. Hladunewich. "Pregnancy and Glomerular Disease." Clinical Journal of the American Society of Nephrology 12, no. 11 (May 18, 2017): 1862–72. http://dx.doi.org/10.2215/cjn.00130117.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Gopal, Raju A., Shrikrishna V. Acharya, Tushar R. Bandgar, Padma S. Menon, and Nalini S. Shah. "Cushing disease with pregnancy." Gynecological Endocrinology 28, no. 7 (May 2, 2012): 533–35. http://dx.doi.org/10.3109/09513590.2011.632789.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Villablanca, Amparo C. "Heart disease during pregnancy." Postgraduate Medicine 104, no. 4 (October 1998): 183–92. http://dx.doi.org/10.3810/pgm.1998.10.460.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Villablanca, Amparo C. "Heart disease during pregnancy." Postgraduate Medicine 104, no. 5 (November 1998): 149–55. http://dx.doi.org/10.3810/pgm.1998.11.407.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Elliott, C., K. Sliwa, and R. Burton. "Pregnancy and cardiac disease." South African Medical Journal 104, no. 9 (August 3, 2014): 641. http://dx.doi.org/10.7196/samj.8762.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Arafeh, J., and Y. Y. El-Sayed. "Cardiac Disease in Pregnancy." NeoReviews 5, no. 6 (June 1, 2004): e232-e239. http://dx.doi.org/10.1542/neo.5-6-e232.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Nanda, Surabhi, Catherine Nelson-Piercy, and Lucy Mackillop. "Cardiac disease in pregnancy." Clinical Medicine 12, no. 6 (December 2012): 553–60. http://dx.doi.org/10.7861/clinmedicine.12-6-553.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Frise, Charlotte J., and Catherine Williamson. "Endocrine disease in pregnancy." Clinical Medicine 13, no. 2 (April 2013): 176–81. http://dx.doi.org/10.7861/clinmedicine.13-2-176.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Baldeweg, Stephanie E. "Endocrine disease in pregnancy." Clinical Medicine 13, no. 4 (August 2013): 417.1–417. http://dx.doi.org/10.7861/clinmedicine.13-4-417.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Avramenko, T. V. "Thyroid Disease and Pregnancy." HEALTH OF WOMAN, no. 4(110) (May 30, 2016): 10–13. http://dx.doi.org/10.15574/hw.2016.110.10.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Melo, João D., Bráulio Gomes, José P. Leite, and Mercedes Agúndez. "McArdle Disease and Pregnancy." Galicia Clínica 76, no. 4 (2015): 169. http://dx.doi.org/10.22546/34/823.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Stagnaro-Green, Alex. "PREGNANCY AND THYROID DISEASE." Immunology and Allergy Clinics of North America 14, no. 4 (November 1994): 865–78. http://dx.doi.org/10.1016/s0889-8561(22)00349-6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Tejeswini, Dr P. Lakshmi, and Dr Nandhini Elumalai. "Addison’s Disease in Pregnancy." IOSR Journal of Dental and Medical Sciences 16, no. 03 (March 2017): 22–23. http://dx.doi.org/10.9790/0853-1603102223.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Rachkonda, Lakshmi, Suresh Rawte, and Swati Shiradkar. "Cardiovascular Disease and Pregnancy." Indian Journal of Maternal-Fetal and Neonatal Medicine 3, no. 1 (2016): 27–35. http://dx.doi.org/10.21088/ijmfnm.2347.999x.3116.6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Quinlivan, Julie A., and Louise C. O'Halloran. "Dariers disease and pregnancy." Dermatology Aspects 1, no. 1 (2013): 1. http://dx.doi.org/10.7243/2053-5309-1-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Quinlivan, Julie A., and Louise C. O'Halloran. "Dariers disease and pregnancy." Dermatology Aspects 1, no. 1 (2013): 2. http://dx.doi.org/10.7243/2053-5309-1-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Lee, Noel M., and Carla W. Brady. "Liver disease in pregnancy." World Journal of Gastroenterology 15, no. 8 (2009): 897. http://dx.doi.org/10.3748/wjg.15.897.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Clark, Steven L. "Cardiac Disease in Pregnancy." Obstetrics and Gynecology Clinics of North America 18, no. 2 (June 1991): 237–56. http://dx.doi.org/10.1016/s0889-8545(21)00270-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Mcilvaine, Susan, Loryn Feinberg, and Melissa Spiel. "Cardiovascular Disease in Pregnancy." NeoReviews 22, no. 11 (November 1, 2021): e747-e759. http://dx.doi.org/10.1542/neo.22-11-e747.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Cardiovascular disease remains a major contributor to rising maternal morbidity and mortality. Both the pregnant woman and fetus are exposed to many potential complications as a result of the physiologic changes of pregnancy. These changes can exacerbate existing cardiac disease, as well as lead to the development of de novo issues during gestation, delivery, and the postnatal period. For women with preexisting cardiac disease, including congenital malformations, valvular disease, coronary artery disease, and aortopathies, it is crucial that they receive multidisciplinary evaluation, counseling, and optimization before conception, as well as close monitoring and medication management during pregnancy. Close monitoring is also essential for patients who develop cardiovascular complications such as preeclampsia, cardiomyopathy, congestive heart failure, coronary events, and arrhythmias during pregnancy. In addition, concerning disparities in maternal morbidity and mortality exist across many dimensions, in part because of the lack of uniformity of care in different treatment settings. Establishment of multidisciplinary cardio-obstetric teams including representatives from cardiology, anesthesia, obstetrics, maternal-fetal medicine, and specialized nursing has proven instrumental to delivering evidence-based and equitable care to high-risk patients. Multidisciplinary teams should work to guide these patients through the preconception, antepartum, delivery, and postpartum phases to ensure appropriate care for weeks to years after pregnancy.

34

Araújo, Amanda Carolina Mendes, Maeli da Silva Antunes, Geice Gabrieli Ribeiro Rocha, Márcia Ramos de Paulo, and Gleison Faria. "Pregnancy-specific hypertensive disease." International Journal of Advanced Engineering Research and Science 8, no. 10 (2021): 174–78. http://dx.doi.org/10.22161/ijaers.810.19.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Yousaf, Farah. "PREGNANCY WITH CARDIAC DISEASE;." Professional Medical Journal 24, no. 01 (January 18, 2017): 106–9. http://dx.doi.org/10.29309/tpmj/2017.24.01.490.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Objective: Objective of study was to find out prevalence and fetal and maternaloutcome in pregnancy with cardiac disease. Study design: A retrospective descriptive study.Setting: Services Hospital Department of Obs and Gynae unit-2. Period: 1st January to 31stDecember 2015. Methodology: All cardiac patients who delivered after 28 week gestation wereincluded in the study. Case-notes of cardiac patients were reviewed, patients age, parity andgestational age was recorded. Maternal and fetal outcome was noted in relation with NYHAclassification, data was analyzed. Results: In our study prevalence of cardiac disease was 1.09%. Age of most patients were between 26-30 years, 44.68%. Most of patients were multiparous57.44%. According to NYHA classification, 63.82% had class 3 & 4 cardiac disease. Rheumaticheart disease was present in 91.48%. Thirty patients were delivered by caesarean section. Therewere 3 IUD and 2 perinatal deaths. Maternal mortality was 2.12%. Preterm delivery occurredin 20 patients. Conclusion: Cardiac disease is important cause of maternal and perinatalmorbidity and mortality. It’s important to counsel all women of reproductive age with knowncardiac disease, about increased fetal and maternal risk during pregnancy. Cesarean sectionmay be considered in patients with moderate or severe MS with class 3-4 symptoms.

36

Mohan, Naina, and Catherine Nelson-Piercy. "Neurological disease in pregnancy." Obstetrics, Gynaecology & Reproductive Medicine 32, no. 1 (January 2022): 14–19. http://dx.doi.org/10.1016/j.ogrm.2021.11.003.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Babadjanova Guljakhon Sattarovna and Uzakova Manzura Kamilovna. "Heart disease in pregnancy." GSC Biological and Pharmaceutical Sciences 15, no. 3 (June 30, 2021): 116–23. http://dx.doi.org/10.30574/gscbps.2021.15.3.0151.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Heart disease are common condition in pregnant women. Even, some of the cases diagnose just during the pregnancy. In this article, we summarize common cardiac disorders, which might encounter during the pregnancy and after birth. Furthermore, we discuss some etiological factors, pathophysiology, clinical manifestation, treatment and outcomes of the cardiac disease in pregnancy.

38

Heffner, John E., and Steven A. Sahn. "PLEURAL DISEASE IN PREGNANCY." Clinics in Chest Medicine 13, no. 4 (December 1992): 667–78. http://dx.doi.org/10.1016/s0272-5231(21)01134-5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Valassi, Elena. "Pituitary disease and pregnancy." Endocrinología, Diabetes y Nutrición (English ed.) 68, no. 3 (March 2021): 184–95. http://dx.doi.org/10.1016/j.endien.2020.07.002.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Dadkhah, Narjeskhaton, Bahareh Motaghi, and Leili Abedi Gheshlaghi. "Pregnancy and coronavirus disease." Journal of Multidisciplinary Care 10, no. 2 (June 30, 2021): 54–55. http://dx.doi.org/10.34172/jmdc.2021.10.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Gungor, A. N. C., G. Kalkan, S. Oguz, B. Sen, P. Ozoguz, Z. Takci, H. Sacar, F. B. Dogan, and D. Cicek. "Behcet disease and pregnancy." Clinical and Experimental Obstetrics & Gynecology 41, no. 6 (December 10, 2014): 617–19. http://dx.doi.org/10.12891/ceog16762014.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Asselin-Miller, Natasha, and Charlotte Patient. "Renal disease in pregnancy." Obstetrics, Gynaecology & Reproductive Medicine 32, no. 3 (March 2022): 27–31. http://dx.doi.org/10.1016/j.ogrm.2022.01.001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Nakash, A., A. Arafa, and T. Datta. "Heart disease in pregnancy." Journal of Obstetrics and Gynaecology 29, no. 8 (January 2009): 767–68. http://dx.doi.org/10.3109/01443610903182839.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Yadav, Vikas, and Ankita Priya. "Cardiovascular Disease in Pregnancy." Scholars International Journal of Obstetrics and Gynecology 02, no. 11 (November 30, 2019): 288–92. http://dx.doi.org/10.36348/sijog.2019.v02i11.007.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Parent, Emily, Joseph R. Wax, Wendy Smith, Hagen Blaszyk, Michael G. Pinette, Angelina Cartin, and Jacquelyn Blackstone. "Fabry disease complicating pregnancy." Journal of Maternal-Fetal & Neonatal Medicine 23, no. 10 (February 2010): 1253–56. http://dx.doi.org/10.3109/14767050903580391.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Kim, Jong In. "Thyroid disease in pregnancy." Journal of the Korean Medical Association 59, no. 1 (2016): 31. http://dx.doi.org/10.5124/jkma.2016.59.1.31.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

vander Weiden, R. M. F. "Hydatid disease in pregnancy." Journal of Obstetrics and Gynaecology 10, no. 2 (January 1989): 128–29. http://dx.doi.org/10.3109/01443618909151130.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Rychik, Jack. "Pregnancy and cardiovascular disease." Expert Review of Cardiovascular Therapy 8, no. 6 (June 2010): 759–61. http://dx.doi.org/10.1586/erc.10.40.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Mikkelse, A. L., and C. Palle. "Lyme disease during pregnancy." Acta Obstetricia et Gynecologica Scandinavica 66, no. 5 (January 1987): 477–78. http://dx.doi.org/10.3109/00016348709022058.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Albert, Eva, Knut Dalaker, Rolf Jorde, and Lillian Nordbø Berge. "Addison's Disease and Pregnancy." Acta Obstetricia et Gynecologica Scandinavica 68, no. 2 (January 1989): 185–87. http://dx.doi.org/10.3109/00016348909009909.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.